

Metallomics

Accepted Manuscript



This is an *Accepted Manuscript*, which has been through the Royal Society of Chemistry peer review process and has been accepted for publication.

Accepted Manuscripts are published online shortly after acceptance, before technical editing, formatting and proof reading. Using this free service, authors can make their results available to the community, in citable form, before we publish the edited article. We will replace this *Accepted Manuscript* with the edited and formatted *Advance Article* as soon as it is available.

You can find more information about *Accepted Manuscripts* in the [Information for Authors](#).

Please note that technical editing may introduce minor changes to the text and/or graphics, which may alter content. The journal's standard [Terms & Conditions](#) and the [Ethical guidelines](#) still apply. In no event shall the Royal Society of Chemistry be held responsible for any errors or omissions in this *Accepted Manuscript* or any consequences arising from the use of any information it contains.

1
2
3 **Small angle X-ray scattering analysis of Cu²⁺-induced oligomers of**
4 **the Alzheimer's amyloid β peptide.**
5
6

7
8 Timothy M. Ryan^{1*}, Nigel Kirby², Haydyn D.T. Mertens^{2,3}, Blaine Roberts¹, Kevin J.
9 Barnham^{1,4}, Roberto Cappai⁴, Chi Le Lan Pham^{3,5}, Colin L. Masters¹ and Cyril C.
10 Curtin^{1,4}
11
12

13
14
15 ¹*University of Melbourne, Florey Institute of Neuroscience and Mental Health,*
16 *Victoria 3010, Australia*
17

18
19 ²*SAXS/WAX Beamline, The Australian Synchrotron, 800 Blackburn Road Clayton,*
20 *Victoria 3168, Australia*
21

22
23 ³*Present address Biological Small Angle Scattering Group European Molecular*
24 *Biology Laboratory c/o DESY Notkestrasse 85, Geb. 25a22603 Hamburg, Germany*
25

26
27 ⁴*Department of Pathology, Bio21 Molecular Science and Technology Institute, The*
28 *University of Melbourne Victoria, 3010, Australia*
29

30
31 ⁵*Present address School of Molecular Bioscience, DO6 Blackburn Building, The*
32 *University of Sydney NSW 2006 Australia*
33

34
35
36
37 ** Corresponding author; Dr T. M. Ryan, Florey Institute of Neuroscience and Mental*
38 *Health, Level 4, Kenneth Myer Building at Genetics Lane on Royal Parade*
39 *Parkville, Vic 3010 tmryan@unimelb.edu.au, Ph: +61390356728*
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Abstract

Research into causes of Alzheimer's disease and its treatment has produced tantalising array of hypotheses about the role of transition metal dyshomeostasis, many of them on the interaction of these metals with the neurotoxic amyloid- β peptide ($A\beta$). Here, we have used small angle X-ray scattering (SAXS) to study the effect of the molar ratio, $Cu^{2+}/A\beta$, on the early three-dimensional structures of the $A\beta_{1-40}$ and $Cu^{2+}/A\beta_{1-42}$ peptides in solution. We found that at molar ratios of 0.5 copper to peptide $A\beta_{1-40}$ aggregated, while $A\beta_{1-42}$ adopted a relatively monodisperse cylindrical shape, and at a ratio of 1.5 copper to peptide $A\beta_{1-40}$ adopted a monodisperse cylindrical shape, while $A\beta_{1-42}$ adopted the shape of an ellipsoid of rotation. We also found, via in-line rapid mixing SAXS analysis, that both peptides in the absence of copper were monodisperse at very short timeframes (<2 sec). Kratky plots of these scattering profiles indicated that immediately after mixing both were intrinsically disordered. Ensemble optimisation modelling reflected this, indicating a wide range of structural conformers. These data reflect the ensembles from which the Cu^{2+} -promoted oligomers were derived. Our results are discussed in the light of other studies that have shown that the $Cu^{2+}/A\beta$ has a marked effect on fibril and oligomer formation by this peptide, with a higher ratio favouring the formation of cytotoxic non-amyloid oligomers. Our results are relatively consistent with previous two-dimensional studies of the conformations of these Cu^{2+} -induced entities, made on a much longer time-scale than SAXS, by transmission electron microscopy and atomic force microscopy, which showed that a range of oligomeric species are formed. We propose that SAXS carried out on a modern synchrotron beamline enables studies on initial events in disordered protein folding on physiologically-relevant time-scales,

1
2
3 and will likely provide great insight into the initiating processes of the A β misfolding,
4
5 oligomerisation and amyloid formation.
6
7
8
9

10 **Introduction:**

11
12 Progressive neurodegeneration associated with deposits of aggregated amyloid
13
14 β peptide (A β) in plaques in the brain is the hallmark of Alzheimer's disease (AD).
15
16 The condition, which poses a major public health burden in all aging populations, is
17
18 characterised by an individually variable decline in cognitive function and selective
19
20 neuronal atrophy accompanied by loss of cortical volume in areas involved in
21
22 learning and memory. While there is a weak correlation between plaque load in the
23
24 brains of human subjects and animal models and the rate of cognitive impairment,¹
25
26 mounting evidence suggests that amyloid fibrils themselves are non-toxic end-
27
28 products,² which may represent an equilibrium sink for toxic intermediates.
29
30
31 Consequently, there has been increasing interest in soluble oligomers of A β that seem
32
33 to be particularly toxic³⁻⁷. Unfortunately, synthetic A β is very responsive to *in vitro*
34
35 environmental conditions. Accordingly, very large ranges of toxic oligomeric
36
37 preparations have been reported, including amyloid derived, diffusible ligands
38
39 (ADDLS), globulomers and amylospheroids (for review see Teplow *et al*⁸) This wide
40
41 range of species has complicated the elucidation of their significance in AD
42
43 pathogenesis⁹.
44
45
46 One factor that significantly influences A β aggregation is the presence of ions of
47
48 transition metals, particularly copper and zinc. These ions can significantly affect the
49
50 formation of both oligomers and amyloid fibrils *in vitro*. In addition, there is some
51
52 evidence that metal dyshomeostasis in the ageing brain may contribute to the
53
54
55
56
57
58
59
60

1
2
3 development of AD, with extra-cellular copper pools being regarded as a potentially
4 critical factor in the development of the disease¹⁰.

5
6
7 Some studies have shown Cu^{2+} at sub-equimolar metal ion/peptide ratios can induce
8 the aggregation of $\text{A}\beta_{1-42}$ into Thioflavin T (ThT) positive fibrils, while at supra-
9 equimolar ratios non-fibrillar oligomers are formed that have been shown to be toxic
10 to neuronal cells in culture¹¹⁻¹³. Other studies have found that both sub and supra-
11 molecular Cu^{2+} /peptide led to the ThT-negative species, implying the absence of
12 cross- β -sheet structures^{14,15}. This dichotomy is intriguing, and may have its basis in
13 the method of preparation of $\text{A}\beta$, which can vary significantly, and can result in
14 dramatically different biophysical properties of the peptide (for example see Ryan *et*
15 *al.*¹⁶).

16
17
18 However, little is known about the structural differences between the oligomers and
19 fibrils that might account for these differences in toxicity. Transmission electron
20 microscopy showed $\text{A}\beta_{1-42}$ in the presence of 1:1 Mole/Mole (M/M) or greater Cu^{2+}
21 forms spheres approximately 10-20 nm in size, while at <1:1 M/M fibrils were
22 observed¹¹. In another study using transmission electron microscopy and atomic
23 force microscopy granular structures were found with $\text{A}\beta_{1-42}$ in the presence of supra-
24 equimolar Cu^{2+} ¹², while at supra-equimolar Cu^{2+} $\text{A}\beta_{1-40}$ formed thin ribbon-like
25 structures that resemble amyloid fibres^{12,17}. The molecular basis for these alternate
26 morphologies is elusive, and warrants further investigation to determine the basis for
27 the disparate toxicity levels.

28
29
30 Small-angle X-ray scattering (SAXS) is a widely used low-resolution technique for
31 structural characterisation of proteins in solution¹⁸. Recent developments in *ab initio*
32 modelling based on the data extracted from the scattering profiles enable the
33 quantitative characterisation of the in solution structures of very large protein
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 assemblages, which either fail to crystallise, and hence cannot be investigated by X-
4
5 ray crystallography, are relatively short lived or are too large to be analysed by
6
7 solution state NMR. Solid-state NMR can achieve relatively high-resolution
8
9 measures; however this technique only gives a representation of the final aggregated
10
11 (and hence solid) conformation. Here, we describe a SAXS study of the earliest A β ₁₋
12
13 ₄₀ and A β ₁₋₄₂ structures formed in the presence of sub- and supra-equimolar ratios of
14
15 Cu²⁺.
16
17

18 **Materials and methods**

19 *A β preparation.*

20
21 Dry Synthetic A β ₁₋₄₀ and A β ₁₋₄₂ (Keck laboratories, Yale) were weighed and
22
23 dissolved in hexafluoro-2-isopropanol (HFIP) and incubated at 25°C for 1 h to remove
24
25 any preformed aggregates. The peptides were then aliquotted into equal amounts and
26
27 dried by using a speed-vac. Before use, aliquots were dissolved in 15 mM NaOH,
28
29 sonicated in a water bath containing ice for 15 min and centrifuged in a bench-top
30
31 centrifuge at 16,000 x g for 20 min. The final peptide concentration was 3.75 mg/mL
32
33 (as determined spectrophotometrically, with 214nm absorbance and extinction
34
35 coefficients of 95426 mol⁻¹ cm⁻¹ and 91264 mol⁻¹ cm⁻¹ for A β ₁₋₄₂ and A β ₁₋₄₀). This was
36
37 diluted fivefold with a buffer consisting of 10 mM sodium phosphate, 150 mM NaCl
38
39 at pH 7.4, followed by sonication with a probe at 0.5 s intervals for 1 min at 30%
40
41 power. The solution was then centrifuged in a benchtop centrifuge at 13,000 rpm for
42
43 20 min.
44
45

46
47 Previously, we have observed that A β ₁₋₄₂ peptides in the absence of copper aggregate
48
49 relatively rapidly, resulting in a solution that is polydisperse, and hence not
50
51 appropriate for SAXS measurements. Thus, a custom, in-line rapid mixing device
52
53 was developed to monitor A β refolding directly after buffer neutralisation. Scattering
54
55
56
57
58
59
60

1
2
3 measurements of the two forms of A β rapidly mixed from 15 mM KOH into the 10
4 mM phosphate 150 mM NaCl pH 7.4 buffer (i.e. without Cu²⁺) were made with a
5 custom built flow mixing apparatus. This consisted of a stainless steel 0.8 mm
6 internal diameter “Y” shaped mixing piece connected to two microsyringes; one
7 syringe delivering 100 μ L of buffer and the sample syringe 10 μ L of protein in KOH.
8
9
10
11
12
13
14 The 1.5 mm quartz capillary located in the SAXS beam was joined to the outlet of the
15 mixing piece by a 15 cm length of 0.8 mm internal diameter silicone tubing. Prior to
16 the SAXS measurements, the efficiency of mixing was determined by measuring
17 photometrically the distribution in the capillary of dye injected into the system at
18 different flow rates. However because of concerns regarding reaction of the Cu²⁺
19 with the steel tubing and syringe plungers introducing Fe ions into the system¹⁹ the
20 apparatus was not used in the experiments where Cu²⁺ was added to the peptides.
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Trace Fe ions in combination with Cu²⁺ can set up a Fenton redox cycle that could lead to oxidative damage to the peptides, even within the short time-scale of our experiment²⁰.

Here, 25 mM Cu²⁺ was prepared as 1 part CuCl₂ to 6 parts glycine (Gly) in H₂O. The addition of a glycine counter-ion was essential to prevent the formation of insoluble phosphate Cu complexes. Because of the known tendency of A β ₁₋₄₀ and A β ₁₋₄₂ to show signs of aggregation in the presence of Cu²⁺ within times as short as 30 min.¹⁹, the CuCl₂/Gly was added to the reaction mixture at the required concentration from the 25 mM stock solution immediately before the SAXS measurements. Buffer equilibration was performed on a PD-10 desalting column (GE Healthcare) equilibrated with the CuCl₂/Gly 10 mM sodium phosphate 150 mM NaCl pH 7.4 buffer, resulting in a final concentration of 100 μ M of protein. Samples were centrifuged at 16,000 x g for 10 minutes and immediately introduced into the SAXS

1
2
3 beamline. The whole process took place within 20 min. Protein concentration of an
4 aliquot of each sample was determined by using the extinction coefficient at 214nm of
5
6
7 $95,426 \text{ M}^{-1} \text{ cm}^{-1}$ and $91,264 \text{ M}^{-1} \text{ cm}^{-1}$ for $\text{A}\beta_{1-42}$ and $\text{A}\beta_{1-40}$, respectively.
8
9

10 *Small- angle X-ray scattering (SAXS) measurements*

11
12 Measurements were made using the high-intensity undulator source on the
13
14 SAXS/WAXS beamline of the Australian Synchrotron (Clayton, Victoria,
15
16 Australia)²¹. An energy resolution of 10^{-4} was obtained from a cryo-cooled Si (III)
17
18 double-crystal monochromator, and the beam size (fwhm focused at the sample) was
19
20 $250 \times 100 \mu\text{m}$ with a total photon current of approximately $2 \times 10^{12} \text{ photons sec}^{-1}$. The
21
22 maximum q range used was 0.005 to 0.35 \AA^{-1} (where $q = 4\pi \sin \theta/\lambda$, 2θ is the X-ray
23
24 scattering angle and λ the X-ray wavelength, 1.03 \AA). Absolute intensities were
25
26 calibrated using water in the 1.5 mm ID quartz capillary. The samples were slowly
27
28 pumped through 1.5 mm quartz capillaries (Hampton Research, Aliso Viejo, CA
29
30 USA) and 25 exposures were made at 1.2 sec. intervals. The exchange buffer was
31
32 used as the scattering blank.
33
34
35

36 *Analysis of SAXS data*

37
38 All patterns obtained were reduced to one-dimensional profiles of intensity I versus q
39
40 using the Saxes15id software package²². Individual frame profiles were inspected to
41
42 ensure that there were no outliers and that those from the initial exposures were
43
44 identical to those from the last indicating absence of radiation damage or, in the cases
45
46 of the proteins with added Cu^{2+} , changes in oligomerisation. Radius of gyration (R_g)
47
48 calculation using AUTORG, Kratky plots (q vs $q^2 I(q)$), Guinier ($\text{Ln } I(q)$ vs q^2) and
49
50 Porod analyses and the determination of the size and shape of the molecules in
51
52 solution from the SAXS profiles were made using the ATSAS suite of programs
53
54
55
56
57 2.5.0-2 release²³⁻²⁶ available from <http://www.embl->
58
59
60

1
2
3 Hamburg.de/ExternalInfo/Research/Sax/index.html. The data were processed and the
4
5 overall parameters were computed following standard procedures using the program
6
7 PRIMUS. Radii of gyration (\AA) were calculated from both Guinier and pair
8
9 distribution function, $P(r)$, analysis. AUTOPOROD²⁷ and the MULCh server of The
10
11 School of Molecular Biosciences, University of Sydney ([http://smb-](http://smb-research.smb.usyd.edu.au)
12
13 [research.smb.usyd.edu.au](http://smb-research.smb.usyd.edu.au))²⁸ were used to calculate estimated particle volume and
14
15 molecular mass. Data were regularised by the indirect Fourier transformation method
16
17 implemented in the program GNOM²⁹ and were used as input into DAMMIF³⁰
18
19 (online at www.embl-hamburg.de/biosaxs/atsas-online/dammif.php) to build *ab initio*
20
21 models of the protein shapes by simulated annealing. DAMMIF was run 20 times on
22
23 the same input data and the output models were aligned and averaged using
24
25 DAMAVER. Molecular dimensions were estimated using HYPERCHEM[®] and final
26
27 illustrations were prepared with RasMol 2.7.4.

28
29
30
31
32 Where scattering indicated a fully flexible protein, ensemble optimisation modelling
33
34 (EOM) was employed³¹. This approach is based on the generation of a large pool
35
36 (typically 10,000) of theoretical structures derived with side-chain interaction
37
38 constraints from the primary sequence of the protein. The theoretical X-ray scattering
39
40 profiles calculated from these structures are then matched for fit using a genetic
41
42 algorithm against the experimental scattering profile to create an ensemble of best fit
43
44 structures. The parameters of these selected structural give a distribution for the best
45
46 fits for R_g and D_{\max} , which can be used to determine variations in flexibility and
47
48 conformation.
49
50

51 52 **Results**

53
54 *Rapid addition of $A\beta_{1-40}$ and $A\beta_{1-42}$ to non- Cu^{2+} containing buffer leads to rapid*
55
56 *development of polydispersity*
57
58
59
60

1
2
3 conformational space of the $A\beta_{1-40}$ and $A\beta_{1-42}$ monomers and showed that neither
4
5 peptide was completely unstructured, in agreement with our SAXS findings.
6

7 *SAXS profiles of $A\beta_{1-40}$ mixed with sub and supra-equimolar Cu^{2+}*
8

9
10 SAXS analysis of $A\beta$ in the presence of copper resulted in a series of interesting results
11
12 (Figure 2). $A\beta_{1-40}$ in the presence of sub-stoichiometric Cu^{2+} displayed an asymptotic
13
14 increase at low angles (figure 2A, ii), indicative of aggregation, and a nonlinear Guinier
15
16 region, which renders this data unanalysable (figure 2D, ii). For comparison curve iii
17
18 shows the similar 4.8 sec. profile for $A\beta_{1-40}$ rapidly mixed from KOH solution into
19
20 buffer. On the other hand, the profile of $A\beta_{1-40}$ in the presence of supra-stoichiometric
21
22 Cu^{2+} indicated a relatively monodisperse solution (figure 2A, i). A Kratky plot of the
23
24 supra-stoichiometric Cu^{2+} ratio indicated globular structure (Figure 2B), and the particle
25
26 distance distribution function ($P(r)$) (Fig. 2C), in conjunction with Guinier analysis
27
28 (Fig. 2D, i) suggested a monodisperse solution with an R_g and D_{max} of $39.7\pm 1\text{\AA}$ and
29
30 $123\pm 2\text{\AA}$, respectively Table 1). The closeness of the Guinier R_g and that obtained from
31
32 the $P(r)$ calculation (Table 1) also supported the suggestion of monodispersity³².
33
34 Porod and MULCh analysis provided values of 47 ± 3 kDa and 51 ± 1 kDa, respectively.
35
36 These results indicate that $A\beta_{1-40}$ in supra-stoichiometric concentrations of copper forms
37
38 a relatively stable large oligomer.
39
40
41
42

43
44 *SAXS profiles of $A\beta_{1-42}$ equilibrated with sub and supra-equimolar Cu^{2+}*
45

46
47 In contrast to $A\beta_{1-40}$, $A\beta_{1-42}$ is monodisperse in the presence of both supra (profile i)
48
49 and sub (profile ii) stoichiometric concentrations of Cu^{2+} (Fig. 3A). However, the
50
51 scattering data indicates that $A\beta_{1-42}$ has two very distinct conformations in the varying
52
53 concentrations of Cu^{2+} . Kratky analysis indicates that these two profiles represent
54
55 globular structures (Fig. 3B), while evaluation of the particle distance distribution
56
57 function ($P(r)$) with GNOM (Fig.3C) and Guinier analysis (Fig. 3D) indicated that the
58
59
60

1
2
3 R_g 's were $54.5 \pm 1 \text{ \AA}$ and $77 \pm 1 \text{ \AA}$ for the low and high Cu^{2+} ratios, respectively, while
4
5 the values obtained from the $P(r)$ calculation were, respectively, $125.5 \pm 1 \text{ \AA}$ and 185
6
7 $\pm 1 \text{ \AA}$ (Table 1). The Porod and MULCh analysis indicate molecular weights of 96 ± 3
8
9 kDa and $98 \pm 1 \text{ kDa}$ for low Cu^{2+} , respectively, while for high Cu^{2+} values of 158 ± 4
10
11 kDa and $161 \pm 4 \text{ kDa}$, respectively, were obtained. These results strongly suggest that
12
13 $\text{A}\beta_{1-42}$ forms large oligomers of differing conformation on the basis of the
14
15 stoichiometric ratio of Cu^{2+} .
16
17
18
19
20

21 *Ab initio modelling of the high Cu^{2+} /peptide $\text{A}\beta_{1-40}$ and high and low $\text{A}\beta_{1-42}$ complexes*

22
23 The D_{max} values indicate that $\text{A}\beta_{1-40}$ in the presence of high Cu^{2+} and the $\text{A}\beta_{1-42}$ Cu^{2+}
24
25 samples were relatively elongated. In a fitting procedure using the ATSAS program
26
27 BODIES, the scattering profiles of the complexes were approximated by those
28
29 generated from simple homogenous geometrical bodies (Figure 4). Using this
30
31 approach the 1.5 M/M $\text{Cu}^{2+}/\text{A}\beta_{1-40}$ could not be suitably described (with discrepancy,
32
33 $\chi > 2.0$) by any of the cylinder, ellipsoid, sphere or dumb-bell bodies (curve i is an
34
35 attempt at cylinder fit), while that of the 0.5 M/M $\text{Cu}^{2+}/\text{A}\beta_{1-42}$ (ii) was very well
36
37 represented by a cylinder of length 193 \AA and diameter 37 \AA ($\chi = 0.85$). Similarly,
38
39 the 1.5 M/M $\text{Cu}^{2+}/\text{A}\beta_{1-42}$ data (iii) were reasonably fit by an ellipsoid of rotation with
40
41 diameter 110 \AA and max depth 68 \AA ($\chi = 1.6$). Nevertheless, we must bear in mind
42
43 two-dimensional scattering data can give several possible three-dimensional
44
45 structures and the failure of the simple BODIES fitting procedure in the case 1.5 M/M
46
47 $\text{Cu}^{2+}/\text{A}\beta_{1-40}$ illustrates that this procedure is not necessarily infallible.
48
49 In another approach, *ab initio* models were reconstructed from the experimental
50
51 scattering data for each of the three monodisperse samples using the bead modelling
52
53 program DAMMIF³⁴. Clustering analysis based upon the normalised spatial
54
55
56
57
58
59
60

1
2
3 discrepancies between input models was conducted to assess the similarity of the
4
5 reconstructions, where the closer the distance between two pairs of models the more
6
7 closely they resemble each other. The small relative distances between clusters are
8
9 given in Table 2 indicate that the *ab initio* reconstructions for each sample are robust.
10
11 It is likely that the poor fit of the 1.5 M/M Cu²⁺/Aβ₁₋₄₀ profile by any of the BODIES
12
13 shapes was due to the noise at its higher *q* values. Bead modelling is less sensitive to
14
15 this region. The shapes of the bead models produced were essentially extended and
16
17 rod-like for both 1.5 M/M Cu²⁺/Aβ₁₋₄₀ and 0.5 M/M Cu²⁺/Aβ₁₋₄₂ samples, but
18
19 compact and discoidal for 1.5 M/M Cu²⁺/Aβ₁₋₄₂. This was consistent with the Kratky
20
21 plots suggesting that the complexes were relatively globular and likely folded.
22
23 Although the depicted shapes are reasonable solutions for modelling from the
24
25 mathematical point of view, it is desirable to seek confirmation from independent
26
27 data, which are usually crystallographic or NMR derived models of the oligomer
28
29 subunits. Monomeric Aβ in solution, however, is intrinsically unstructured, molecular
30
31 dynamics simulation showing it to populate a range of conformations^{35,36}. This is
32
33 confirmed in our EOM analysis of the scattering data from the rapid mixing
34
35 experiment where at physiological pH and ionic strength both peptides rapidly
36
37 assumed an unstructured conformation before aggregating. However, the Kratky plots
38
39 generated from the SAXS data of the Cu²⁺ complexes are consistent with folded
40
41 peptide in each case, indicating that the binding of Cu²⁺ leads to structural
42
43 stabilisation. Dividing the molecular mass of the 1.5 M/M Cu²⁺/Aβ₁₋₄₂ by the
44
45 molecular mass of Aβ₁₋₄₂ suggests that it consists of 38 peptide monomers, while the
46
47 elongated 1.5 M/M Cu²⁺/Aβ₁₋₄₀ and 0.5 M/M Cu²⁺/Aβ₁₋₄₂ consist of 10 and 20
48
49 peptides, respectively. The length of an extended β strand conformation of Aβ₁₋₄₂ is
50
51 118 Å while that for Aβ₁₋₄₀ is 115 Å. Since the conformations of the complexes are
52
53
54
55
56
57
58
59
60

1
2
3 dependent on the Cu^{2+} /peptide ratio, we would expect the known Cu^{2+} coordination
4 sites, at the N-terminal end of the peptides, to be involved in their formation³⁷⁻⁴⁰. At
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

At the C-terminal half of the peptide there are the two zipper sequences; the Gly-XXX-Gly-XXX-Gly motif that has been proposed to mediate the formation of toxic oligomers⁴¹ and the C-terminal sequence starting at M35⁴². In both kinds of zipper M35 plays a prominent role. Solid-state NMR experiments⁴³ have demonstrated that dimerization of protofibrils involves the formation of an inter-sheet steric zipper via M35–M35 for both $\text{A}\beta_{1-40}$ and $\text{A}\beta_{1-42}$. However, participation of M35 presents an important constraint on the role of both kinds of zipper in the formation of the Cu^{2+} induced oligomers/protofibrils. It has been shown that $\text{A}\beta_{1-42}$ fibrils formed in the presence of Zn^{2+} are resistant to matrix metalloprotease 2, which cleaves $\text{A}\beta$ at L34-M35, while fibrils and protofibrils formed in the presence of 0.1-10 M/M Cu^{2+} are degraded⁴⁴. This finding suggests that the oligomers/protofibrils formed in the presence of Cu^{2+} must be either sufficiently loosely packed to allow access of the protease or are in equilibrium with monomeric species. A possible packing arrangement for the 1.5 M/M Cu^{2+} / $\text{A}\beta_{1-42}$ is shown in the cartoon in Figure 5 where 19 peptides can be fitted into each half of an ellipsoid of rotation of the dimensions indicated by the scattering data. The overlap necessary to fit into the depth of the ellipsoid covers the two above-mentioned zipper regions.

Discussion:

The $\text{A}\beta$ peptides are cleaved from the amyloid- β protein precursor (APP) by the two proteases, β - and γ -secretase. Studies in transgenic mice and cell and hippocampal slice cultures show that $\text{A}\beta$ oligomers modulate both pre- and postsynaptic structures and functions in a dose- and assembly-dependent manner. A major task for the study of the biophysics of $\text{A}\beta$ peptides is to relate *in vitro* observations of their modes of

1
2
3 assembly to what is known of their *in vivo* behaviour. However, establishing this
4
5 relationship is difficult as the *in vitro* and *in vivo* spheres of action have contrasting
6
7 time-scales. On release from the APP into the synaptic cleft the peptides are
8
9 confronted with a *milieu* containing Zn and Cu ions and membrane surfaces within a
10
11 small space that would be conducive to rapid reactions. SAXS performed on a
12
13 synchrotron beamline can generate data on a time-scale of seconds. It, therefore, is a
14
15 good method for studying the collapse of inherently disordered proteins into more
16
17 compact conformers that could be the basis of larger assemblages. NMR studies^{45, 46}
18
19 have been carried out on fibrillar structures in the presence of Cu, using magic angle
20
21 spinning, and on A β in structure promoting environments⁴⁷, while ion mobility
22
23 coupled with mass spectrometry has been used to characterise different oligomer
24
25 states of A β ₁₋₄₀ and A β ₁₋₄₂ in the absence of Cu⁴⁸. They have made a very significant
26
27 contribution to our understanding of the structural relationships between the peptides
28
29 forming amyloids, but typically provide information on events that occur late in the
30
31 aggregation pathway.
32
33
34
35

36 Our findings on the effect of Cu²⁺ on A β folding agree broadly with what is already
37
38 known of the effect of Cu²⁺ concentration on the polymerisation of A β . Smith *et al.*¹¹
39
40 found that at sub-equimolar Cu²⁺/peptide molar ratios A β ₁₋₄₂ formed thioflavin-T
41
42 reactive non toxic fibrils, however at supra-equimolar Cu²⁺/peptide molar ratios it
43
44 formed toxic oligomers. Transmission electron microscopy showed these to be
45
46 approximately 10-20 nm in diameter and associated with large amorphous aggregates.
47
48 Jin *et al.*¹² found that the only significant effect on A β ₁₋₄₀ of equimolar Cu²⁺/peptide
49
50 was to produce thin (proto) fibrils as observed by TEM and AFM. However A β ₁₋₄₂
51
52 showed increased aggregation in the presence of Cu²⁺, which induced granular
53
54 aggregates and enhanced A β ₁₋₄₂'s cytotoxicity. The structure obtained in our SAXS
55
56
57
58
59
60

1
2
3 studies of the supra-equimolar $\text{Cu}^{2+}/\text{A}\beta_{1-42}$ was somewhat smaller in diameter (Fig.
4
5 5C) and consistent with a monodisperse solution of oligomeric discoidal/ellipsoidal
6
7 particles. It is highly likely that these differences are also due to differences in the
8
9 initial aggregation propensity of the different batches of peptide and the method used
10
11 for their initial solubilisation. Significantly, the 7 nm thickness of the ellipsoid of
12
13 rotation is compatible with the estimate of 20 nm for the width of the synaptic cleft⁴⁹
14
15 which is one of the likely sites of $\text{A}\beta$ oligomer toxicity⁵⁰.
16
17

18
19 Smith *et al.*¹¹ showed the presence of dityrosine in the supra-molecular $\text{Cu}^{2+}/\text{A}\beta_{1-42}$
20
21 oligomers. Cu^{2+} induced formation of di-tyrosine may be a mechanistic cause of the
22
23 increase in $\text{A}\beta$ cytotoxicity observed upon treatment with Cu^{2+} ¹¹. Barnham *et al.*⁵¹
24
25 showed that Cu-facilitated redox processes involving tyrosine at position 10 of $\text{A}\beta$
26
27 could produce reactive oxygen species contributing to the cytotoxicity of $\text{A}\beta$ peptides
28
29 in the presence of Cu^{2+} . A feature of this reaction was that it required Cu-Cu distances
30
31 of approximately 6Å, as shown by EPR studies showing dipolar interaction effects in
32
33 the spectra of supra-equimolar $\text{Cu}^{2+}/\text{A}\beta_{1-42}$ that were not observed with sub-equimolar
34
35 preparations⁵². It is, therefore, possible that the compact structure of the discoidal
36
37 oligomers formed in the presence of supra-equimolecular Cu^{2+} concentrations
38
39 demonstrated by our SAXS study would facilitate Cu-Cu interaction and hence
40
41 toxicity, while the more extended structures found at a lower Cu^{2+} concentration may
42
43 not facilitate this arrangement. Alternatively, toxicity may be increased by
44
45 enhancement of cross-linking of synaptic membrane receptors by the $\text{A}\beta$ N-terminal
46
47 regions in the discoidal structure. Cross-linking leading to synaptotoxicity has been
48
49 suggested as an $\text{A}\beta$ toxicity mechanism⁵³.
50
51
52
53
54
55
56
57

58 **Conclusion:**
59
60

1
2
3 We show that sub-equimolecular concentrations of copper ions induce the formation
4
5 of elongated A β structures consistent with protofibrils, while supra-equimolecular
6
7 concentrations of copper ions induce A β ₁₋₄₂ to form ellipsoidal oligomers, consistent
8
9 with postulated toxic oligomeric species that have been observed microscopically.
10
11 The SAXS results show that these structures form rapidly, and are relatively well
12
13 ordered, suggesting that they are likely to interact specifically with larger
14
15 macromolecular structures. In addition, our results show the utility of SAXS in
16
17 understanding the complex behaviour observed in aggregation prone systems, and the
18
19 potential insight that can be gained through rapid analysis of protein folding and self-
20
21 association.
22
23
24
25
26
27

28 **Acknowledgements:**

29
30 The authors wish to acknowledge the support of the Australian Synchrotron and the
31
32 Victorian Government Operational Infrastructure Support Program. TMR is supported
33
34 by the Australian Alzheimer's disease foundation. CLM and KJB are consultants for
35
36 Prana Biotechnology Pty ltd. CLM, KJB and RC are the principal investigators on an
37
38 NHMRC program grant

39 **References**

- 40 1. Lim YY, Ellis KA, Harrington K, Kamer A, Pietrzak RH, Bush AI, Darby D,
41 Martins RN, Masters CL, Rowe CC, Savage G, Szoeka C, Villemagne VL,
42 Ames D and M. P., *Neuropsychology*, 2013, **27**, 322-332.
- 43 2. M. E. Larson and S. E. Lesne, *J Neurochem*, 2012, **120 Suppl 1**, 125-139.
- 44 3. S. Lesne and L. Kotilinek, *J Neurosci*, 2005, **25**, 9319-9320.
- 45 4. S. Lesne, L. Kotilinek and K. H. Ashe, *Neuroscience*, 2008, **151**, 745-749.
- 46 5. G. M. Shankar, B. L. Bloodgood, M. Townsend, D. M. Walsh, D. J. Selkoe
47 and B. L. Sabatini, *J Neurosci*, 2007, **27**, 2866-2875.
- 48 6. G. M. Shankar, S. Li, T. H. Mehta, A. Garcia-Munoz, N. E. Shepardson, I.
49 Smith, F. M. Brett, M. A. Farrell, M. J. Rowan, C. A. Lemere, C. M. Regan,
50 D. M. Walsh, B. L. Sabatini and D. J. Selkoe, *Nat Med*, 2008, **14**, 837-842.
- 51 7. G. M. Shankar, A. T. Welzel, J. M. McDonald, D. J. Selkoe and D. M. Walsh,
52 *Methods Mol Biol*, 2011, **670**, 33-44.
- 53 8. D. B. Teplow, *Alzheimer's research & therapy*, 2013, **5**, 39.
- 54 9. I. Benilova, E. Karran and B. De Strooper, *Nat Neurosci*, 2012, **15**, 349-357.
- 55 10. A. I. Bush, *J Alzheimers Dis*, 2012.
- 56
57
58
59
60

11. D. P. Smith, G. D. Ciccotosto, D. J. Tew, M. T. Fodero-Tavoletti, T. Johanssen, C. L. Masters, K. J. Barnham and R. Cappai, *Biochemistry*, 2007, **46**, 2881-2891.
12. L. Jin, W. H. Wu, Q. Y. Li, Y. F. Zhao and Y. M. Li, *Nanoscale*, 2011, **3**, 4746-4751.
13. J. T. Pedersen, J. Ostergaard, N. Rozlosnik, B. Gammelgaard and N. H. Heegaard, *J Biol Chem*, 2011, **286**, 26952-26963.
14. X. H. Yang, H. C. Huang, L. Chen, W. Xu and Z. F. Jiang, *J Alzheimers Dis*, 2009, **18**, 799-810.
15. M. Mold, L. Ouro-Gnao, B. M. Wieckowski and C. Exley, *Scientific reports*, 2013, **3**, 1256.
16. T. M. Ryan, J. Caine, H. D. Mertens, N. Kirby, J. Nigro, K. Breheney, L. J. Waddington, V. A. Streltsov, C. Curtain, C. L. Masters and B. R. Roberts, *PeerJ*, 2013, **1**, e73.
17. S. Jun and S. Saxena, *Angew Chem Int Ed Engl*, 2007, **46**, 3959-3961.
18. H. D. Mertens and D. I. Svergun, *J Struct Biol*, 2010, **172**, 128-141.
19. C. S. Atwood, R. D. Moir, X. Huang, R. C. Scarpa, N. M. Bacarra, D. M. Romano, M. A. Hartshorn, R. E. Tanzi and A. I. Bush, *J Biol Chem*, 1998, **273**, 12817-12826.
20. M. Brzyska, A. Bacia and D. Elbaum, *European journal of biochemistry / FEBS*, 2001, **268**, 3443-3454.
21. N. M. Kirby, S. T. Mudie, A. M. Hawley, D. J. Cookson, H. D. Mertens, N. Cowieson and V. Samardzic-Boban, *Journal of Applied Crystallography*, 2013, **46**, 1670-1680.
22. D. Cookson, N. Kirby, R. Knott, M. Lee and D. Schultz, *Journal of synchrotron radiation*, 2006, **13**, 440-444.
23. P. V. Konarev, M. V. Petoukhov, V. V. Volkov and D. I. Svergun, *J Appl Crystallography*, 2006, **39**, 277-286.
24. P. V. Konarev, V. V. Volkov, A. V. Sokolova, K. M.H.J. and D. I. Svergun, *J Appl Crystallography* 2003, **36**, 1277-1282.
25. P. V. Konarev, M. V. Petoukhov and D. I. Svergun, *J Appl Crystallography*, 2001, **34**, 527-532.
26. D. I. Svergun, *Biophys J*, 1999, **76**, 2879-2886.
27. M. V. Petoukhov and D. I. Svergun, *The international journal of biochemistry & cell biology*, 2013, **45**, 429-437.
28. A. E. Whitten, S. Cai and J. Trehwella, *J Appl Cryst*, 2008, **41**, 222-226.
29. D. I. Svergun, *J. Appl. Crystallogr.*, 1992, **25**, 495-503.
30. M. V. Petoukhov, D. Franke, A. V. Shkumatov, G. Tria, A. G. Kikhney, M. Gajda, C. Gorba, H. D. T. Mertens, P. V. Konarev and D. I. Svergun, *Journal of Applied Crystallography*, 2012, **45**, 342-350.
31. P. Bernado and D. I. Svergun, *Mol Biosyst*, 2012, **8**, 151-167.
32. D. A. Jaques and J. Trehwella, *Protein Science*, 2010, **19**, 642-657.
33. M. Yang and D. B. Teplow, *Journal of molecular biology*, 2008, **384**, 450-464.
34. D. Franke and D. I. Svergun, *J. Appl. Crystallogr.*, 2009, **42**, 342-346.
35. J. Ikebe, N. Kamiya, J. Ito, H. Shindo and J. Higo, *Protein Sci*, 2007, **16**, 1596-1608.
36. J. P. Colletier, A. Laganowsky, M. Landau, M. Zhao, A. B. Soriaga, L. Goldschmidt, D. Flot, D. Cascio, M. R. Sawaya and D. Eisenberg, *Proc Natl Acad Sci U S A*, 2011, **108**, 16938-16943.

- 1
 - 2
 - 3
 - 4
 - 5
 - 6
 - 7
 - 8
 - 9
 - 10
 - 11
 - 12
 - 13
 - 14
 - 15
 - 16
 - 17
 - 18
 - 19
 - 20
 - 21
 - 22
 - 23
 - 24
 - 25
 - 26
 - 27
 - 28
 - 29
 - 30
 - 31
 - 32
 - 33
 - 34
 - 35
 - 36
 - 37
 - 38
 - 39
 - 40
 - 41
 - 42
 - 43
 - 44
 - 45
 - 46
 - 47
 - 48
 - 49
 - 50
 - 51
 - 52
 - 53
 - 54
 - 55
 - 56
 - 57
 - 58
 - 59
 - 60
37. S. C. Drew and K. J. Barnham, *Acc Chem Res*, 2011, **44**, 1146-1155.
38. S. C. Drew, C. L. Masters and K. J. Barnham, *J Am Chem Soc*, 2009, **131**, 8760-8761.
39. S. C. Drew, C. L. Masters and K. J. Barnham, *PLoS One*, 2010, **5**, e15875.
40. S. C. Drew, C. J. Noble, C. L. Masters, G. R. Hanson and K. J. Barnham, *J Am Chem Soc*, 2009, **131**, 1195-1207.
41. V. Fonte, V. Dostal, C. M. Roberts, P. Gonzales, P. Lacor, J. Magrane, N. Dingwell, E. Y. Fan, M. A. Silverman, G. H. Stein and C. D. Link, *Mol Neurodegener*, 2011, **6**, 61.
42. R. Nelson, M. R. Sawaya, M. Balbirnie, A. O. Madsen, C. Riek, R. Grothe and D. Eisenberg, *Nature*, 2005, **435**, 773-778.
43. T. Sato, P. Kienlen-Campard, M. Ahmed, W. Liu, H. Li, J. I. Elliott, S. Aimoto, S. N. Constantinescu, J. N. Octave and S. O. Smith, *Biochemistry*, 2006, **45**, 5503-5516.
44. P. J. Crouch, D. J. Tew, T. Du, D. N. Nguyen, A. Caragounis, G. Filiz, R. E. Blake, I. A. Trounce, C. P. Soon, K. Laughton, K. A. Perez, Q. X. Li, R. A. Cherny, C. L. Masters, K. J. Barnham and A. R. White, *J Neurochem*, 2009, **108**, 1198-1207.
45. S. Parthasarathy, F. Long, Y. Miller, Y. Xiao, D. McElheny, K. Thurber, B. Ma, R. Nussinov and Y. Ishii, *J Am Chem Soc*, 2011, **133**, 3390-3400.
46. S. Parthasarathy, B. Yoo, D. McElheny, W. Tay and Y. Ishii, *J Biol Chem*, 2014, **289**, 9998-10010.
47. J. D. Gehman, C. C. O'Brien, F. Shabanpoor, J. D. Wade and F. Separovic, *European biophysics journal : EBJ*, 2008, **37**, 333-344.
48. S. L. Bernstein, N. F. Dupuis, N. D. Lazo, T. Wytttenbach, M. M. Condrón, G. Bitan, D. B. Teplow, J. E. Shea, B. T. Ruotolo, C. V. Robinson and M. T. Bowers, *Nat Chem*, 2009, **1**, 326-331.
49. B. Zuber, I. Nikonenko, P. Klauser, D. Muller and J. Dubochet, *PNAS*, 2005, **102**, 19192-19197.
50. H. Kokubo, R. Kayed, C. G. Glabe and H. Yamaguchi, *Brain Res*, 2005, **1031**, 222-228.
51. K. J. Barnham, F. Haeffner, G. D. Ciccotosto, C. C. Curtain, D. Tew, C. Mavros, K. Beyreuther, D. Carrington, C. L. Masters, R. A. Cherny, R. Cappai and A. I. Bush, *FASEB J*, 2004, **18**, 1427-1429.
52. C. C. Curtain, F. Ali, I. Volitakis, R. A. Cherny, R. S. Norton, K. Beyreuther, C. J. Barrow, C. L. Masters, A. I. Bush and K. J. Barnham, *J Biol Chem*, 2001, **276**, 20466-20473.
53. C. Bate and A. Williams, *J Biol Chem*, 2011, **286**, 37955-37963.

Figure legends:

Figure 1: Scattering data from rapid mix experiments. A) Profiles of A β ₁₋₄₀ taken at 1.2 second intervals reading up from lowest curve after mixing from 15 mM KOH solution into 10 mM phosphate 150 mM NaCl pH 7.4 buffer. B) Profiles of A β ₁₋₄₂ taken after mixing, 1.2 sec. intervals between curves also reading up from lowest

1
2
3 curve, C) Kratky plot calculated from the 1st 1.2 sec. A β_{1-40} profile. D) Kratky plot
4
5 from the 1.2 sec. A β_{1-42} profile. E) R_g distribution calculated using Advanced EOM
6
7 2.0 from the 1.2 sec A β_{1-42} profile. F) EOM derived D_{max} distribution for the 1.2 sec
8
9 A β_{1-42} profile. G) EOM derived R_g distribution for the 1.2 sec A β_{1-40} profile. H)
10
11 EOM derived D_{max} distribution for the 1.2 sec A β_{1-40} profile. Dotted lines in panels E,
12
13 F, G and H represent the pools of R_g and D_{max} values generated from the peptide
14
15 sequences. The solid lines represent the ensemble values.
16
17
18
19
20

21 Figure 2: Scattering data for Cu²⁺/A β_{1-40} at sub and supra-equimolecular ratios.

22
23 A) Scattering profiles. Curve (i) A β_{1-40} in 1.5 M/M Cu²⁺, (ii) A β_{1-40} 0.5 M/M Cu²⁺
24
25 B) Kratky plot of 1.5 M/M Cu²⁺/A β_{1-40} . C) Pair distribution analysis plot ($P(r)$) of 1.5
26
27 M/M Cu²⁺/A β_{1-40} . D) Guinier plots of (i) 1.5 M/M Cu²⁺/A β_{1-40} , (ii) 0.5M/M
28
29 Cu²⁺/A β_{1-40} , and (iii) A β_{1-40} rapidly mixed from KOH to buffer.
30
31
32
33
34
35

36 Figure 3: Scattering data for Cu²⁺/A β_{1-42} in sub and supra-equimolecular ratios. A)
37
38 Scattering profiles for (i) A β_{1-42} in 1.5 M/M Cu²⁺, (ii) A β_{1-42} in 0.5 M/M Cu²⁺ and (iii)
39
40 A β_{1-42} in buffer for comparison. B) Kratky plots of (i) 1.5 M/M Cu²⁺/A β_{1-42} , (ii) 0.5
41
42 M/M Cu²⁺/A β_{1-42} . C) Pair distribution analysis plot ($P(r)$) of (i) 1.5 M/M Cu²⁺/A β_{1-42} ,
43
44 (ii) 0.5 M/M Cu²⁺/A β_{1-42} . D) Guinier plot of (i) 1.5 M/M Cu²⁺/A β_{1-42} , (ii) 0.5 M/M
45
46 Cu²⁺/A β_{1-42}
47
48
49
50
51

52 Figure 4: Fit of cylindrical and ellipsoidal bodies to scattering profiles; (i) Lack of fit
53
54 of a cylinder to 1.5 M/M Cu²⁺/A β_{1-42} ; (ii) Fit of a cylinder to the profile of 0.5 M/M
55
56 Cu²⁺/A β_{1-42} ; (iii) Fit of an ellipsoid of rotation to the profile of 1.5 M/M Cu²⁺/A β_{1-42} .
57
58
59
60

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Figure 5: Cartoons of *ab initio* models produced by using DAMMIF of A. 1.5 M/M $\text{Cu}^{2+}/\text{A}\beta_{1-40}$, B. 0.5 M/M $\text{Cu}^{2+}/\text{A}\beta_{1-42}$, C. 1.5 M/M $\text{Cu}^{2+}/\text{A}\beta_{1-42}$, D. side view of ellipsoid of rotation, E and F showing how $\text{A}\beta_{1-42}$ monomers could pack into the shape depicted in panels C and D.

Table 1

Radii of gyration (\AA), D_{max} (\AA) and molecular mass (kDa) of $\text{A}\beta_{1-40}:\text{Cu}^{2+}$ and $\text{A}\beta_{1-42}:\text{Cu}^{2+}$ at sub and supra-equimolecular peptide/Cu ratios

Peptide	R_g Guinier	R_g GNOM	D_{max}	MM AUTOPOROD	MM MULCh
1.5 M/M $\text{Cu}^{2+}/\text{A}\beta_{1-40}$	$39.7\pm 1\text{\AA}$	$43.5\pm 2\text{\AA}$	$123\pm 2\text{\AA}$	47 ± 3 kDa	51 ± 2 kDa
0.5 M/M $\text{Cu}^{2+}/\text{A}\beta_{1-42}$	$54.5\pm 1\text{\AA}$	$58.5\pm 2\text{\AA}$	$125\pm 1\text{\AA}$	96 ± 3 kDa	98 ± 1 kDa
1.5 M/M $\text{Cu}^{2+}/\text{A}\beta_{1-42}$	$77\pm 1\text{\AA}$	$84\pm 1\text{\AA}$	$185\pm 1\text{\AA}$	158 ± 4 kDa	161 ± 4 kDa

Table 2

Relative distances between clusters obtained from DAMMIF

$A\beta_{1-40}$ 1.5M/MCu ²⁺			$A\beta_{1-42}$ 0.5 M/M Cu ²⁺			$A\beta_{1-42}$ 1.5 M/M Cu ²⁺		
Clusters		distances*	Clusters		distances*	Clusters		distances*
1	2	0.5050	1	2	0.5576	1	2	0.6924
1	3	0.5239	1	3	0.5944	1	3	0.6287
1	4	0.5124	1	4	0.5836	1	4	0.6251
1	5	0.5164	1	5	0.5684	1	5	0.7118
1	6	0.5296	1	6	0.6209	1	6	0.6385
1	7	0.5208	1	7	0.5861	1	7	0.6299
2	3	0.5401	2	3	0.6225	2	3	0.7599
2	4	0.5366	2	4	0.6030	2	4	0.6625
2	5	0.5231	2	5	0.5490	2	5	0.6742
2	6	0.5306	2	6	0.5506	2	6	0.5527
2	7	0.5336	2	7	0.5532	2	7	0.7793
3	4	0.5463	3	4	0.5925	3	4	0.7521
3	5	0.5397	3	5	0.6236	3	5	0.7730
3	6	0.5620	3	6	0.5660	3	6	0.6214
3	7	0.5508	3	7	0.6219	3	7	0.7242
4	5	0.5712	4	5	0.5968	4	5	0.6993
4	6	0.5467	4	6	0.6542	4	6	0.5897
6	7	0.5730	6	7	0.6235	6	7	0.7728
5	6	0.5543	5	6	0.5660	5	6	0.6722
5	7	0.5792	5	7	0.6036	5	7	0.6960

*Truncated from 13 places




Figure 1: Scattering data from rapid mix experiments. A) Profiles of A β 1-40 taken at 1.2 second intervals reading up from lowest curve after mixing from 15 mM KOH solution into 10 mM phosphate 150 mM NaCl pH 7.4 buffer. B) Profiles of A β 1-42 taken after mixing, 1.2 sec. intervals between curves also reading up from lowest curve, C) Kratky plot calculated from the 1st 1.2 sec. A β 1-40 profile. D) Kratky plot from the 1.2 sec. A β 1-42 profile. E) R $_g$ distribution calculated using Advanced EOM 2.0 from the 1.2 sec A β 1-42 profile. F) EOM derived D $_{max}$ distribution for the 1.2 sec A β 1-42 profile. G) EOM derived R $_g$ distribution for the 1.2 sec A β 1-40 profile. H) EOM derived D $_{max}$ distribution for the 1.2 sec A β 1-40 profile. Dotted lines in panels E, F, G and H represent the pools of R $_g$ and D $_{max}$ values generated from the peptide sequences. The solid lines represent the ensemble values.

190x254mm (96 x 96 DPI)




Figure 2: Scattering data for Cu²⁺/Aβ₁₋₄₀ at sub and supra-equimolecular ratios. A) Scattering profiles. Curve (i) Aβ₁₋₄₀ in 1.5 M/M Cu²⁺, (ii) Aβ₁₋₄₀ 0.5 M/M Cu²⁺ B) Kratky plot of 1.5 M/M Cu²⁺/Aβ₁₋₄₀. C) Pair distribution analysis plot ($P(r)$) of 1.5 M/M Cu²⁺/Aβ₁₋₄₀. D) Guinier plots of (i) 1.5 M/M Cu²⁺/Aβ₁₋₄₀, (ii) 0.5 M/M Cu²⁺/Aβ₁₋₄₀, and (iii) Aβ₁₋₄₀ rapidly mixed from KOH to buffer.

254x190mm (96 x 96 DPI)




Figure 3: Scattering data for Cu²⁺/Aβ1-42 in sub and supra-equimolecular ratios. A) Scattering profiles for (i) Aβ1-42 in 1.5 M/M Cu²⁺, (ii) Aβ1-42 in 0.5 M/M Cu²⁺ and (iii) Aβ1-42 in buffer for comparison.

B) Kratky plots of (i) 1.5 M/M Cu²⁺/Aβ1-42, (ii) 0.5 M/M Cu²⁺/Aβ1-42. C) Pair distribution analysis plot ($P(r)$) of (i) 1.5 M/M Cu²⁺/Aβ1-42, (ii) 0.5 M/M Cu²⁺/Aβ1-42.

D) Guinier plot of (i) 1.5 M/M Cu²⁺/Aβ1-42, (ii) 0.5 M/M Cu²⁺/Aβ1-42.

254x190mm (96 x 96 DPI)




Figure 4: Fit of cylindrical and ellipsoidal bodies to scattering profiles; (i) Lack of fit of a cylinder to 1.5 M/M Cu²⁺/A β 1-42 ; (ii) Fit of a cylinder to the profile of 0.5 M/M Cu²⁺/A β 1-42; (iii) Fit of an ellipsoid of rotation to the profile of 1.5 M/M Cu²⁺/A β 1-42.
190x275mm (96 x 96 DPI)




Figure 5: Cartoons of ab initio models produced by using DAMMIF of A. 1.5 M/M Cu²⁺/A β 1-40 , B. 0.5 M/M Cu²⁺/A β 1-42, C. 1.5 M/M Cu²⁺/A β 1-42, D. side view of ellipsoid of rotation, E and F showing how A β 1-42 monomers could pack into the shape depicted in panels C and D.
254x190mm (96 x 96 DPI)